Royalty Pharma Plc

$37.50 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About Royalty Pharma Plc

Royalty Pharma plc is engaged in investing in late stage biopharmaceutical products. The Company invests in academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The Company’s portfolio of pharmaceutical investment includes investments in commercial products and development-stage product candidates. Its portfolio investments include AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko, Trikafta and OXLUMO.

Stock Analysis

last close $37.5
1-mo return 3.3%
3-mo return -7.1%
avg daily vol. 1.25M
52-week high 53.23
52-week low 34.8
market cap. $16.4B
forward pe 12.6
annual div. 0.68
roe 19.6%
ltg forecast 11.9%
dividend yield 1.81%
annual rev. $2.2B
inst own. 59.1%

Subscribe now for daily local and international financial news